Skip to the page

Data / Drug companies / Jubilant DraxImage Inc., DBA Jubilant Radiopharma

Jubilant DraxImage Inc., DBA Jubilant Radiopharma: 9 products in the FDA NDC directory, labeler code 65174

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Jubilant DraxImage Inc., DBA Jubilant Radiopharma (labeler code 65174) lists 9 products in the FDA National Drug Code Directory, covering 6 finished drugs by generic name. By type: 9 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on December 4, 2023.

The request: Watch Jubilant DraxImage Inc., DBA Jubilant Radiopharma (FDA labeler code 65174): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
65174
Products in commercial distribution
9
Packages
11
Finished drugs by generic name
6
Prescription products
9
Over the counter products
0
Flagged as original packager
9 of 9 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
December 30, 1987
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)777.8%
Generic drugs (ANDA)111.1%
Biologics (BLA)111.1%

Products by type

TypeProductsShare
Prescription drugs9100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Sodium iodide i 13121
Technetium tc 99m sulfur colloid kit11
Technetium tc 99m mertiatide11
Technetium tc 99m medronate12
Rubidium rb 8211
Kit for the preparation of technetium tc 99m pentetate12

Dosage forms

Dosage formProductsShare
Injection, powder, lyophilized, for solution333.3%
Injection, powder, for solution222.2%
Kit111.1%
Injection, solution111.1%
Solution111.1%
Capsule111.1%

Pharmacologic classes

FDA established pharmacologic classes of its products.

ClassProducts
Radioactive Diagnostic Agent2
Radioactive Therapeutic Agent2
Lead Chelator1

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Kit for the Preparation of Technetium Tc 99m Sulfur Colloid65174-179KitGeneric drugs (ANDA)December 4, 2023
TECHNETIUM Tc 99m MERTIATIDE65174-261Injection, powder, lyophilized, for solutionNew drug applications (NDA)March 31, 2023
Drax Exametazime65174-200Injection, powder, lyophilized, for solutionNew drug applications (NDA)August 17, 2017
Ruby-fill65174-021Injection, solutionNew drug applications (NDA)September 30, 2016
Sodium Iodide I 131 Diagnostic65174-461CapsuleNew drug applications (NDA)May 1, 2006
Technetium Tc 99m Medronate65174-660Injection, powder, for solutionNew drug applications (NDA)February 27, 2004
Hicon65174-880SolutionNew drug applications (NDA)April 7, 2003
Draximage dtpa65174-288Injection, powder, lyophilized, for solutionNew drug applications (NDA)December 29, 1989
Draximage maa65174-270Injection, powder, for solutionBiologics (BLA)December 30, 1987

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.